Pharmacologic management of patients with both heart failure and diabetes

[1]  Grant D. Huang,et al.  Glucose control and vascular complications in veterans with type 2 diabetes. , 2009, The New England journal of medicine.

[2]  J. McMurray,et al.  Discordant Short- and Long-Term Outcomes Associated With Diabetes in Patients With Heart Failure: Importance of Age and Sex: A Population Study of 5.1 Million People in Scotland , 2008, Circulation. Heart failure.

[3]  Alfonso T. Perez,et al.  Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction. , 2008, Journal of cardiac failure.

[4]  Michael E. Miller,et al.  Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.

[5]  Diederick Grobbee,et al.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.

[6]  J. O’Keefe,et al.  Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS , 2008, Diabetes, obesity & metabolism.

[7]  J. Dora,et al.  Standards of Medical Care in Diabetes—2008 , 2008, Diabetes Care.

[8]  R. McKelvie,et al.  Diabetes, left ventricular systolic dysfunction, and chronic heart failure. , 2008, European heart journal.

[9]  A. Bhalla,et al.  Images in clinical medicine. Paget's disease of the mandible. , 2008, The New England journal of medicine.

[10]  R. Nesto,et al.  Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials , 2007, The Lancet.

[11]  F. McAlister,et al.  Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review , 2007, BMJ : British Medical Journal.

[12]  S. Nissen,et al.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.

[13]  J. McMurray,et al.  A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. , 2007, Journal of the American College of Cardiology.

[14]  Anne L. Taylor,et al.  Early and Sustained Benefit on Event-Free Survival and Heart Failure Hospitalization From Fixed-Dose Combination of Isosorbide Dinitrate/Hydralazine: Consistency Across Subgroups in the African-American Heart Failure Trial , 2007, Circulation.

[15]  R. Shannon,et al.  Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. , 2006, Journal of cardiac failure.

[16]  Salim Yusuf,et al.  Predictors of mortality and morbidity in patients with chronic heart failure. , 2006, European heart journal.

[17]  Ross T Tsuyuki,et al.  Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. , 2005, Diabetes care.

[18]  H. Krumholz,et al.  Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure: An Observational Study , 2005, Circulation.

[19]  P. Deedwania,et al.  Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. , 2005, American heart journal.

[20]  G. Fonarow,et al.  Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. , 2005, American heart journal.

[21]  Ralph D'Agostino,et al.  Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. , 2004, The New England journal of medicine.

[22]  S. Solomon,et al.  Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction: Results of the CHARM Low–Left Ventricular Ejection Fraction Trials , 2004, Circulation.

[23]  R. Shannon,et al.  Recombinant Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake and Improves Left Ventricular Performance in Conscious Dogs With Pacing-Induced Dilated Cardiomyopathy , 2004, Circulation.

[24]  L. Rydén,et al.  Tolerability of carvedilol and ACE‐Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE‐Inhibitor Remodelling Mild CHF EvaluatioN) , 2004, European journal of heart failure.

[25]  S. Wild,et al.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.

[26]  S. Grundy,et al.  Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A Consensus Statement From the American Heart Association and American Diabetes Association , 2003, Diabetes care.

[27]  E. Salpeter,et al.  Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. , 2003, Archives of internal medicine.

[28]  T. Vos,et al.  Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. , 2003, American heart journal.

[29]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.

[30]  M. Pfeffer,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial , 2003, The Lancet.

[31]  Paul G Shekelle,et al.  Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. , 2003, Journal of the American College of Cardiology.

[32]  A. Keogh,et al.  CHART: congestive cardiac failure in hospitals, an Australian review of treatment. , 2003, Heart, lung & circulation.

[33]  J. Cohn,et al.  A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. , 2001, The New England journal of medicine.

[34]  W. Hermann,et al.  Results from post‐hoc analyses of the CIBIS II trial: effect of bisoprolol in high‐risk patient groups with chronic heart failure , 2001 .

[35]  A. Siebenhofer,et al.  Betablocker treatment in diabetes mellitus , 2001, Journal of internal medicine.

[36]  Larkin Rj,et al.  Spironolactone in patients with heart failure. , 2000 .

[37]  G. Glick.  Spironolactone in patients with heart failure. , 2000, The New England journal of medicine.

[38]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[39]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[40]  Philip D. Harvey,et al.  Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39 , 1998, BMJ.

[41]  J. Evans,et al.  ACE Inhibitor Use Is Associated With Hospitalization for Severe Hypoglycemia in Patients With Diabetes , 1997, Diabetes Care.

[42]  W. Ray,et al.  Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. , 1997, JAMA.

[43]  R. Marfella,et al.  Metabolic and Cardiovascular Effects of Carvedilol and Atenolol in Non-Insulin-Dependent Diabetes Mellitus and Hypertension , 1997, Annals of Internal Medicine.

[44]  Australia..  Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease , 1997, The Lancet.

[45]  K. Adams,et al.  Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. , 1996, Circulation.

[46]  R. Herings,et al.  Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme , 1995, The Lancet.

[47]  S. Yusuf,et al.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.

[48]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[49]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.

[50]  P. Cryer,et al.  Oral Propranolol and Metoprolol Both Impair Glucose Recovery from Insulin-induced Hypoglycemia in Insulin-dependent Diabetes Mellitus , 1984, Diabetes Care.